ArticleJournal of thoracic disease2024

Preoperative administration of camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): study protocol of a single-arm, open-label, phase II study.

Hang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.